Semin Thromb Hemost
DOI: 10.1055/s-0036-1597902
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome

Hannah Cohen1, 2, Maria Efthymiou1, Carolyn Gates3, David Isenberg4, 5
  • 1Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
  • 2Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • 3Department of Pharmacy, University College London Hospitals NHS Foundation Trust, London, United Kingdom
  • 4Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
  • 5Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
Further Information

Publication History

Publication Date:
14 February 2017 (eFirst)

Abstract

The current mainstay of the treatment and secondary thromboprophylaxis of thrombotic antiphospholipid syndrome (APS) is anticoagulation with warfarin or other vitamin K antagonists (VKAs). In addition to their well-known limitations, VKAs are often problematic in APS patients because of the variable sensitivity of thromboplastins to lupus anticoagulant. As a result, the international normalized ratio may not accurately reflect the intensity of anticoagulation. Direct oral anticoagulants (DOACs) are established as therapeutic alternatives to VKAs for a wide range of indications, including the treatment and secondary prevention of venous thromboembolism. Definition of the role of DOACs in the treatment of thrombotic APS is emerging with the results of recent and ongoing clinical studies. This review focuses on the current situation with regard to DOACs for secondary thromboprophylaxis in APS and issues pertinent to DOAC use in APS patients, as well as potential future directions.